A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

Clinical trial NCT03565003 · COMPLETED

Trial details

NCT number: NCT03565003
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Head and Neck Cancer Esophageal Cancer Other Metastatic Solid Tumors

Start date: 2018-11-20
Primary completion: 2023-01-31
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.